Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, today announced that
screening is underway in Study SRP-9003-301. Also known as
EMERGENE, Study 9003-301 is a Phase 3, multi-national, open-label
study of SRP-9003 (bidridistrogene xeboparvovec) for the treatment
of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4), or beta
sarcoglycanopathy. EMERGENE will enroll 15 participants (ambulatory
and non-ambulatory), aged 4 and older, and uses commercially
representative process SRP-9003 material.
“We are pleased to share our continued progress in advancing
SRP-9003, our investigational gene therapy candidate for LGMD2E, a
rare form of LGMD with no treatments beyond symptom management.
Early results from the SRP-9003 clinical development program
demonstrated significant protein expression at both 12-weeks and
two years after treatment as well as functional benefits including
slowing progression of this disease, improving mobility, and
enhancing the quality of life for individuals living with LGMD2E,”
said Louise Rodino-Klapac, Ph.D., executive vice president, chief
scientific officer and head of research and development, Sarepta
Therapeutics. “In addition to its importance for the LGMD2E
community, EMERGENE will inform the clinical development of other
programs for LGMD in Sarepta’s pipeline while serving as a
pathfinder for viable regulatory pathways to support the
development of gene therapies to treat ultra rare diseases.”
A webinar for the limb-girdle community is planned, details will
be shared at a future date.
About SRP-9003 (bidridistrogene xeboparvovec)
SRP-9003 (bidridistrogene xeboparvovec) is an investigational
gene therapy that uses the AAVrh74 vector, which is designed to be
systemically and robustly delivered to skeletal, diaphragm and
cardiac muscle, making it an ideal candidate to treat neuromuscular
diseases. SRP-9003 is intended to deliver a full-length
beta-sarcoglycan transgene and uses the MHCK7 promoter, chosen for
its ability to robustly express in the heart, which is critically
important for patients with limb-girdle muscular dystrophy Type 2E
(LGMD2E), also known as beta-sarcoglycanopathy and LGMDR4, many of
whom die from pulmonary or cardiac complications.
About Study SRP-9003-301 (EMERGENE)
EMERGENE, Study 9003-301 is a Phase 3, multinational, open-label
study of SRP-9003 for the treatment of LGMD2E in 15 ambulatory and
non-ambulatory participants, ages 4 and older. The EMERGENE design
incorporates a six-month natural history lead-in. The primary
endpoint is expression of beta-sarcoglycan 60 days after dosing.
Other endpoints include functional measures through month 60 and
safety.
About Limb-girdle Muscular Dystrophy
Limb-girdle muscular dystrophies are genetic diseases that cause
progressive, debilitating weakness and wasting that begins in
muscles around the hips and shoulders before progressing to muscles
in the arms and legs. Sarepta’s six LGMD gene therapy programs in
development include LGMD2E/R4, LGMD2D, LGMD2C, LGMD2B, LGMD2L and
LGMD2A, which together represent more than 70 percent of known LGMD
cases.
Patients with LGMD2E (beta-sarcoglycanopathy) begin showing
neuromuscular symptoms such as difficulty running, jumping and
climbing stairs before age 10. The disease, which is an autosomal
recessive subtype of LGMD, progresses to loss of ambulation in the
teen years and often leads to early mortality. There are currently
no disease modifying treatments for LGMD2E.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic
medicine for rare diseases that devastate lives and cut futures
short. We hold leadership positions in Duchenne muscular dystrophy
(DMD) and limb-girdle muscular dystrophies (LGMDs), and we
currently have more than 40 programs in various stages of
development. Our vast pipeline is driven by our multi-platform
Precision Genetic Medicine Engine in gene therapy, RNA and gene
editing. For more information, please visit www.sarepta.com or
follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors
in the 'For Investors' section of our website at www.sarepta.com.
We encourage investors and potential investors to consult our
website regularly for important information about us.
Forward-Looking Statements
This press release contains “forward-looking statements.” Any
statements that are not statements of historical fact may be deemed
to be forward-looking statements. Words such as “believe,”
“anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,”
“look,” “potential,” “possible” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements include, without limitation, statements
relating to our future operations, technologies and scientific
approaches, business plans, priorities, research and development
programs; and the potential benefits of SRP-9003.
Actual results could materially differ from those stated or
implied by these forward-looking statements as a result of such
risks and uncertainties. Known risk factors include the following:
our data may not be sufficient for obtaining regulatory approval;
success in preclinical and clinical trials, especially if based on
a small patient sample, does not ensure that later clinical trials
will be successful, and the results of future research may not be
consistent with past positive results or with advisory committee
recommendations, or may fail to meet regulatory approval
requirements for the safety and efficacy of product candidates; we
may not be able to comply with all FDA requests in a timely manner
or at all; the possible impact of regulations and regulatory
decisions by the FDA and other regulatory agencies on our business;
the commencement and completion of our clinical trials and
announcement of results may be delayed or prevented for a number of
reasons, including, among others, denial by the regulatory agencies
of permission to proceed with our clinical trials, or placement of
a clinical trial on hold, challenges in identifying, recruiting,
enrolling and retaining patients to participate in clinical trials
and inadequate quantity or quality of supplies of a product
candidate or other materials necessary to conduct clinical trials;
different methodologies, assumptions and applications we use to
assess particular safety or efficacy parameters may yield different
statistical results, and even if we believe the data collected from
clinical trials of our product candidates are positive, these data
may not be sufficient to support approval by the FDA or other
global regulatory authorities; we may not be able to execute on our
business plans, including meeting our expected or planned
regulatory milestones and timelines, research and clinical
development plans, and bringing our product candidates to market,
for various reasons, many of which may be outside of our control,
including possible limitations of company financial and other
resources, manufacturing limitations that may not be anticipated or
resolved for in a timely manner, regulatory, court or agency
decisions, such as decisions by the United States Patent and
Trademark Office with respect to patents that cover our product
candidates; and those risks identified under the heading “Risk
Factors” in our most recent Annual Report on Form 10-K for the year
ended December 31, 2022, and Form 10-Q filed with the Securities
and Exchange Commission (SEC) as well as other SEC filings made by
the Company, which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect
the Company’s business, results of operations and the trading price
of Sarepta’s common stock. For a detailed description of risks and
uncertainties Sarepta faces, you are encouraged to review the SEC
filings made by Sarepta. We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release. Sarepta does not undertake any obligation to
publicly update its forward-looking statements based on events or
circumstances after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240116971158/en/
Investors: Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media: Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Grafico Azioni Sarepta Therapeutics (NASDAQ:SRPT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Sarepta Therapeutics (NASDAQ:SRPT)
Storico
Da Mag 2023 a Mag 2024